4) NAVIGATOR Study Group: Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 362: 1463-1476, 2010.
5) Chiasson JL, et al: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290: 486-494, 2003.